FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968594753> ?p ?o ?g. }

• W2968594753 endingPage "159" @default.
• W2968594753 startingPage "148" @default.
• W2968594753 abstract "Summary Background The 5-year survival rate for extensive-disease small-cell lung carcinoma (ED-SCLC) is only 1%. Recently, apatinib exerted promising effects on cancer patients after failure of first-line chemotherapy. Methods This study enrolled 24 ED-SCLC patients to study the efficacy and toxicity of apatinib in combination with chemotherapy and maintenance therapy. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints included toxicity and safety. Apatinib was given 250 mg/day during the chemotherapy interval, and as maintenance therapy after 4–6 cycles until the patient progressed, died, or was intolerant to drug toxicity. The study further evaluated the cytotoxicity, cell-cycle arrest and apoptotic induction of apatinib in A549 and H446 cells. Results There was no difference in short-term efficacy between combined and chemotherapy groups. Long-term efficacy showed that the median PFS was 7.8 months and 4.9 months in combination and chemotherapy groups, respectively [ p = 0.002, HR(95%CI): 0.18(0.06–0.60)]. The median OS was 12.1 months and 8.2 months in combination and chemotherapy groups, respectively [ p = 0.023, HR(95%CI): 0.38 (0.16–0.90)]. Multivariate Cox regression analysis showed that apatinib combined with chemotherapy was an independent prognostic factor for OS and PFS. The ECOG score was an independent prognostic factor affecting OS. In vitro analysis showed that apatinib inhibited cell proliferation and caused cell-cycle arrest and apoptosis. Conclusion Apatinib combination/maintenance therapy showed promising efficacy and safety to extend OS/PFS in ED-SCLC and will be a potent therapeutic option in future practice. Although the scale of this study is small, further research on large sample sizes is needed." @default.
• W2968594753 created "2019-08-22" @default.
• W2968594753 creator A5002092628 @default.
• W2968594753 creator A5012339079 @default.
• W2968594753 creator A5012804068 @default.
• W2968594753 creator A5058094308 @default.
• W2968594753 creator A5059779870 @default.
• W2968594753 creator A5064478014 @default.
• W2968594753 creator A5065636474 @default.
• W2968594753 creator A5066599847 @default.
• W2968594753 creator A5069130770 @default.
• W2968594753 creator A5085751424 @default.
• W2968594753 date "2019-08-09" @default.
• W2968594753 modified "2023-10-15" @default.
• W2968594753 title "A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first­line induction chemotherapy in extensive­ stage small cell lung cancer" @default.
• W2968594753 cites W2015833202 @default.
• W2968594753 cites W2047170687 @default.
• W2968594753 cites W2101663915 @default.
• W2968594753 cites W2105968397 @default.
• W2968594753 cites W2108045918 @default.
• W2968594753 cites W2117692326 @default.
• W2968594753 cites W2119404465 @default.
• W2968594753 cites W2124473529 @default.
• W2968594753 cites W2129638180 @default.
• W2968594753 cites W2132556766 @default.
• W2968594753 cites W2136290128 @default.
• W2968594753 cites W2145708352 @default.
• W2968594753 cites W2151730005 @default.
• W2968594753 cites W2155599713 @default.
• W2968594753 cites W2158898314 @default.
• W2968594753 cites W2170260373 @default.
• W2968594753 cites W2296028965 @default.
• W2968594753 cites W2418354692 @default.
• W2968594753 cites W2480201404 @default.
• W2968594753 cites W2527905628 @default.
• W2968594753 cites W2570532684 @default.
• W2968594753 cites W2586697182 @default.
• W2968594753 cites W2588150967 @default.
• W2968594753 cites W2607215639 @default.
• W2968594753 cites W2614467469 @default.
• W2968594753 cites W2675354485 @default.
• W2968594753 cites W2745840031 @default.
• W2968594753 cites W2747989445 @default.
• W2968594753 cites W2767796090 @default.
• W2968594753 cites W2767807681 @default.
• W2968594753 cites W2787426491 @default.
• W2968594753 cites W2796582438 @default.
• W2968594753 cites W2884947885 @default.
• W2968594753 cites W2892640821 @default.
• W2968594753 cites W2893960509 @default.
• W2968594753 cites W2934520391 @default.
• W2968594753 cites W4250428608 @default.
• W2968594753 doi "https://doi.org/10.1007/s10637-019-00828-x" @default.
• W2968594753 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6985106" @default.
• W2968594753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31399906" @default.
• W2968594753 hasPublicationYear "2019" @default.
• W2968594753 type Work @default.
• W2968594753 sameAs 2968594753 @default.
• W2968594753 citedByCount "17" @default.
• W2968594753 countsByYear W29685947532019 @default.
• W2968594753 countsByYear W29685947532020 @default.
• W2968594753 countsByYear W29685947532021 @default.
• W2968594753 countsByYear W29685947532022 @default.
• W2968594753 countsByYear W29685947532023 @default.
• W2968594753 crossrefType "journal-article" @default.
• W2968594753 hasAuthorship W2968594753A5002092628 @default.
• W2968594753 hasAuthorship W2968594753A5012339079 @default.
• W2968594753 hasAuthorship W2968594753A5012804068 @default.
• W2968594753 hasAuthorship W2968594753A5058094308 @default.
• W2968594753 hasAuthorship W2968594753A5059779870 @default.
• W2968594753 hasAuthorship W2968594753A5064478014 @default.
• W2968594753 hasAuthorship W2968594753A5065636474 @default.
• W2968594753 hasAuthorship W2968594753A5066599847 @default.
• W2968594753 hasAuthorship W2968594753A5069130770 @default.
• W2968594753 hasAuthorship W2968594753A5085751424 @default.
• W2968594753 hasBestOaLocation W29685947531 @default.
• W2968594753 hasConcept C121608353 @default.
• W2968594753 hasConcept C126322002 @default.
• W2968594753 hasConcept C141071460 @default.
• W2968594753 hasConcept C143998085 @default.
• W2968594753 hasConcept C168563851 @default.
• W2968594753 hasConcept C203092338 @default.
• W2968594753 hasConcept C2776256026 @default.
• W2968594753 hasConcept C2776694085 @default.
• W2968594753 hasConcept C2778283404 @default.
• W2968594753 hasConcept C2780668389 @default.
• W2968594753 hasConcept C29730261 @default.
• W2968594753 hasConcept C71924100 @default.
• W2968594753 hasConcept C90924648 @default.
• W2968594753 hasConceptScore W2968594753C121608353 @default.
• W2968594753 hasConceptScore W2968594753C126322002 @default.
• W2968594753 hasConceptScore W2968594753C141071460 @default.
• W2968594753 hasConceptScore W2968594753C143998085 @default.
• W2968594753 hasConceptScore W2968594753C168563851 @default.
• W2968594753 hasConceptScore W2968594753C203092338 @default.
• W2968594753 hasConceptScore W2968594753C2776256026 @default.
• W2968594753 hasConceptScore W2968594753C2776694085 @default.
• W2968594753 hasConceptScore W2968594753C2778283404 @default.

• next